Amphotericin B: Mechanistic Insights for Fungal Infection...

2026-01-12

Amphotericin B: Mechanistic Insights for Fungal Infection Research

Executive Summary: Amphotericin B is an amphipathic polyene antifungal antibiotic produced by Streptomyces nodosus and widely used in fungal infection research due to its high potency and defined mechanism of action (APExBIO B1885). It targets ergosterol in fungal membranes, forming pores that disrupt ion gradients and induce cell death (Amphotericin B: Mechanisms and Research Benchmarks). Amphotericin B can activate immune pathways such as NF-κB via TLR2 and CD14, and is a validated tool in prion disease models. Biofilm resistance and toxicity to mammalian cells (via cholesterol interaction) remain key considerations. This article enumerates mechanistic evidence, experimental best practices, and clearly marks limitations, referencing recent peer-reviewed research (Shen et al. 2025).

Biological Rationale

Amphotericin B is a gold-standard polyene antifungal antibiotic for investigating fungal pathogens, especially Candida albicans and related species. Its amphipathic structure enables selective targeting of ergosterol-rich fungal membranes while sparing most mammalian cells, though toxicity remains a concern due to partial cholesterol binding (Polyene Antifungal Mechanisms & Research Standards). This selectivity underpins its use in comparative studies of fungal versus mammalian membrane integrity and for dissecting antifungal resistance in biofilm-forming species. The emergence of multidrug-resistant fungi and the complexity of biofilm biology highlight the need for validated reference compounds like Amphotericin B (Shen et al. 2025). Its immune-modulatory properties, notably via TLR2 and CD14, render it valuable for probing innate immune responses.

Mechanism of Action of Amphotericin B

Amphotericin B binds ergosterol in fungal cell membranes, inserting its hydrophobic polyene chain into the lipid bilayer. This interaction induces the formation of aqueous pores, increasing membrane permeability to small cations (K⁺, Na⁺) and anions (Cl^-), leading to ion imbalance and fungal cell death (Amphotericin B: Mechanisms). The IC₅₀ for Amphotericin B against representative C. albicans isolates ranges from 0.028 to 0.290 μg/mL under standard in vitro conditions (RPMI-1640, 35°C, 24 h). While affinity for ergosterol is high, Amphotericin B can also interact with mammalian cholesterol, explaining dose-limiting toxicity in cell-based and animal studies. In immune cells, Amphotericin B activates NF-κB via TLR2/CD14-dependent pathways, driving inflammatory cytokine release. This dual action enables its use in both direct antifungal and immunomodulation assays.

Evidence & Benchmarks

Amphotericin B disrupts ergosterol-containing fungal membranes, forming pores that allow influx/efflux of ions and small molecules (Shen et al. 2025, https://doi.org/10.1016/j.identj.2025.103873).
In C. albicans biofilms, Amphotericin B maintains activity, but efficacy is reduced when autophagy is upregulated, as shown by decreased drug susceptibility upon rapamycin treatment (Shen et al. 2025, https://doi.org/10.1016/j.identj.2025.103873).
Amphotericin B (SKU B1885, APExBIO) is soluble at ≥46.2 mg/mL in DMSO but insoluble in water and ethanol; recommended storage is at -20°C (https://www.apexbt.com/amphotericin-b.html).
Experimental concentrations in cell-based assays typically range from 1–4 μg/mL for optimal antifungal activity (APExBIO, https://amyloid-peptide-10-20-human.com/index.php?g=Wap&m=Article&a=detail&id=15884).
In animal models of transmissible spongiform encephalopathies, Amphotericin B reduces pathological prion protein (PrP^Sc) accumulation and prolongs survival (Shen et al. 2025, https://doi.org/10.1016/j.identj.2025.103873).
Amphotericin B induces TLR2/CD14-dependent cytokine release and NF-κB activation in macrophages and HEK293 cells, supporting its use in immune signaling pathway research (https://tak-242.com/index.php?g=Wap&m=Article&a=detail&id=43).

Applications, Limits & Misconceptions

Amphotericin B serves as a reference antifungal in cell viability, biofilm, and immune pathway assays. Its reliability in disrupting ergosterol-rich fungal membranes allows for benchmarking new compounds and studying resistance mechanisms. The compound’s documented effects in prion disease models and immune cell activation expand its utility beyond antifungal research. However, context-specific pitfalls and misconceptions persist.

Common Pitfalls or Misconceptions

Misconception: Amphotericin B is equally effective against all fungal biofilms.
Fact: Biofilms with upregulated autophagy show increased resistance (Shen et al. 2025, DOI).
Misconception: Water is a suitable solvent for stock preparations.
Fact: Amphotericin B is insoluble in water; DMSO is recommended (APExBIO, product page).
Misconception: Amphotericin B is stable for long-term storage in solution.
Fact: Stock solutions should not be stored long-term once dissolved; fresh preparation is advised (APExBIO).
Misconception: Selectivity for ergosterol ensures negligible mammalian toxicity.
Fact: Amphotericin B can disrupt mammalian membranes via cholesterol binding, causing cytotoxicity at higher doses.
Misconception: All immune activation by Amphotericin B is TLR2-dependent.
Fact: While TLR2/CD14 are primary, other pathways may be involved, especially at high concentrations.

This article builds on prior overviews such as "Amphotericin B (SKU B1885): Reliable Solutions for Fungal...", by providing newly peer-reviewed evidence on autophagy-mediated biofilm resistance and clarifying precise experimental parameters.

Workflow Integration & Parameters

For experimental work, APExBIO’s Amphotericin B (SKU B1885) is supplied as a lyophilized solid. Dissolve in DMSO to ≥46.2 mg/mL for stock solutions. Avoid use of water or ethanol, as the compound is insoluble in these solvents. Prepare fresh aliquots before each experiment and store at -20°C. In cell-based assays, apply at 1–4 μg/mL unless otherwise justified. Confirm membrane disruption via propidium iodide or similar exclusion assays. For immune pathway studies, use validated reporter lines (e.g., NF-κB luciferase HEK293) and include TLR2/CD14 controls. In prion disease models, follow published dosing regimens (e.g., intraperitoneal injections at 0.5–1 mg/kg in rodents). Refer to Amphotericin B (SKU B1885): Reliable Solutions for Fungal... for troubleshooting and advanced workflows; this article updates that guidance with autophagy-related resistance benchmarks.

Conclusion & Outlook

Amphotericin B (SKU B1885) from APExBIO remains a foundational tool for dissecting fungal membrane biology, immune pathway activation, and prion disease mechanisms. While its mechanism is well-characterized, evolving insights into resistance—particularly from biofilm and autophagy research—demand careful experimental design. Proper solvent selection, dosing, and awareness of immune and cytotoxic effects are essential. Researchers are encouraged to integrate updated evidence and consult peer-reviewed sources to optimize experimental outcomes.